Fidelity Advisor® Biotechnology Z (FIJYX)

Add to Watchlists
Create an Alert
27.46 -0.16  -0.58% Aug 22 USD
View Full Chart
Total Returns Chart

Performance & Returns

  Total Return Cat. Total Return (NAV) % Rank in Cat. (NAV)
1M -0.04% -0.89% 18
3M 1.18% 2.75% 70
6M -1.08% 0.44% 39
YTD 9.66% 11.42% 53
1Y -- -3.37% --
3Y -- 8.90% --
5Y -- 8.24% --
10Y -- 14.49% --
15Y -- 10.89% --
20Y -- 10.18% --
As of Aug. 22, 2019. Returns for periods of 1 year and above are annualized.

Asset Allocation

Type % Net % Long % Short
Cash 1.19% 1.19% 0.00%
Stock 98.30% 98.30% 0.00%
Bond 0.00% 0.00% 0.00%
Convertible 0.00% 0.00% 0.00%
Preferred 0.51% 0.51% 0.00%
Other 0.00% 0.00% 0.00%
As of June 30, 2019

Region Exposure

Americas 97.13%
North America 97.13%
Latin America 0.00%
Greater Europe 2.57%
United Kingdom 0.00%
Europe Developed 2.57%
Europe Emerging 0.00%
Africa/Middle East 0.00%
Greater Asia 0.30%
Japan 0.00%
Australasia 0.00%
Asia Developed 0.00%
Asia Emerging 0.30%
Market Classification
% Developed Markets 99.70%
% Emerging Markets 0.30%
As of June 30, 2019. Region breakdown data is calculated by using the long position holdings of the portfolio.

Stock Sector Exposure

Basic Materials 0.00%
Communication Services 0.00%
Consumer Cyclical 0.00%
Consumer Defensive 0.00%
Energy 0.00%
Financial Services 0.00%
Healthcare 100.0%
Industrials 0.00%
Real Estate 0.00%
Technology 0.00%
Utilities 0.00%
As of June 30, 2019

Stock Market Capitalization

Giant 23.57%
Large 32.90%
Medium 25.04%
Small 15.51%
Micro 2.98%
As of June 30, 2019

Stock Style Exposure

Large Cap Value 30.59%
Large Cap Blend 19.45%
Large Cap Growth 10.67%
Mid Cap Value 0.00%
Mid Cap Blend 0.00%
Mid Cap Growth 24.63%
Small Cap Value 0.45%
Small Cap Blend 4.01%
Small Cap Growth 10.19%
As of June 30, 2019
View More Holdings

Top 10 Holdings

Symbol Name % Weight Price % Chg
ABBV AbbVie Inc 16.25% 66.43 -1.61%
VRTX Vertex Pharmaceuticals Inc 9.64% 181.75 -1.35%
ALXN Alexion Pharmaceuticals Inc 8.83% 115.70 -6.31%
CELG Celgene Corp 8.74% 94.73 -1.02%
AMGN Amgen Inc 6.76% 199.90 -1.73%
GILD Gilead Sciences Inc 4.62% 63.01 -1.88%
NBIX Neurocrine Biosciences Inc 2.66% 98.37 +1.16%
SRPT Sarepta Therapeutics Inc 2.22% 94.42 -0.68%
SAGE Sage Therapeutics Inc 2.21% 169.59 +0.28%
ASND Ascendis Pharma A/S ADR 2.20% 114.42 -1.23%
As of June 30, 2019
Advertisement

One Page Reports

Basic Info

Style
Equity Style Large Cap/Growth
Broad Asset Class Sector Equity
Broad Category Equity
Category Name Health
Prospectus Objective Specialty - Health
Fund Owner Firm Name Fidelity Investments
Benchmark Index
S&P 500 TR USD
100.0%

Manager Info

Name Tenure
Eirene Kontopoulos 0.88 yrs

Net Fund Flows

1M -39.12M
3M -149.11M
6M -246.68M
YTD -268.85M
1Y -417.79M
3Y -1.106B
5Y 298.20M
10Y 1.438B
As of July 31, 2019

Risk Info

Beta (5Y) --
Historical Sharpe Ratio (10Y) --
Historical Sortino (All) --
Daily Value at Risk (VaR) 1% (All) 4.14%
Monthly Value at Risk (VaR) 1% (All) 11.05%

Fundamentals

Dividend Yield TTM (8-22-19) 0.00%
30-Day SEC Yield --
7-Day SEC Yield --
Weighted Average PE Ratio 19.61
Weighted Average Price to Sales Ratio 6.736
Weighted Average Price to Book Ratio 5.675
Weighted Median ROE 8.65%
Weighted Median ROA -2.77%
Forecasted Dividend Yield 1.58%
Forecasted PE Ratio 11.68
Forecasted Price to Sales Ratio 5.168
Forecasted Price to Book Ratio 4.535
Number of Holdings 82
As of June 30, 2019

Growth Estimates

Forecasted 5 Yr Earnings Growth 12.59%
Forecasted Book Value Growth 8.34%
Forecasted Cash Flow Growth 14.66%
Forecasted Earnings Growth 17.50%
Forecasted Revenue Growth 14.13%
As of June 30, 2019

Comparables

Edit

Attributes

Purchase Details
Open to New Investors Yes
Open to Existing Investors Yes
Minimum Initial Investment 0.00 USD
Minimum Subsequent Investment 0.00 USD
Fees
Actual 12B-1 Fee --
Actual Management Fee 0.54%
Administration Fee --
Performance Fee --
Switching Fee --
Transaction Fee --
Maximum Front Load --
Maximum Deferred Load --
Maximum Redemption Fee --
Key Dates
Inception Date 10/2/2018
Termination Date
Last Annual Report Date
Last Prospectus Date 9/29/2018
Attributes
Exchange Traded Share No
Exchange Traded Note No
Enhanced Index Fund No
Fixed Distribution Fund No
High-Net Worth Individual Fund No
Index Fund No
Inverse Fund No
Leveraged Fund No
Fund of Funds No
Currency Hedged Fund No
Synthetic Replication Fund No
Has Dividend Investment Plan No
Socially Responsible Fund No
General Availability
Available for Insurance Product No
Available for Retirement Plan No
Available for RRSP No

Excel Add-In Codes

  • Name: =YCI("M:FIJYX","name")
  • Broad Asset Class: =YCI("M:FIJYX", "broad_asset_class")
  • Broad Category: =YCI("M:FIJYX", "broad_category_group")
  • Prospectus Objective: =YCI("M:FIJYX", "prospectus_objective")

To find the codes for any of our financial metrics, see our Complete Reference of Metric Codes.

Access our powerful Excel Add-in with a YCharts Professional Membership. Learn More.

Advertisement

{{root.upsell.info.feature_headline}}.

{{root.upsell.info.feature_description}}

Please note that this feature is only available as an add-on to YCharts subscriptions.


Please note that this feature requires full activation of your account and is not permitted during the free trial period.

Start My Free Trial {{root.upsell.info.call_to_action}} No credit card required.

Already a subscriber? Sign in.